• 作者：Anna Cabré ; Iolanda Lá ; zaro ; Nú ; ria Plana ; Raimó ; n Ferre ; Jordi Merino ; Lluí ; s Masana ; ^{luis.masana@urv.cat}
• 关键词：FABP4 ; S&iacute ; ndrome metab&oacute ; lico ; Progresi&oacute ; n ; Regresi&oacute ; n
• 刊名：Cl铆nica e Investigaci贸n en Arteriosclerosis
• 出版年：2010
• 期刊代码：pca88_02149168
• 类别：med
• 出版时间：November-December 2010
• 卷：22
• 期：6
• 页码：247-255
• 文件大小：266 K

Background

Circulating FABP4 levels have been associated with metabolic alterations and have been considered a predictive biomarker of the development of metabolic syndrome (MS), independently of adiposity and insulin resistance in non-diabetic Asians.

Objective

To evaluate the relationship between changes in FABP4 levels and MS regression or progression in a group of subjects enrolled in a therapeutic lifestyle changes program.

Patients and methods

We included 140 subjects with abdominal obesity and increased overall cardiovascular risk, who were prospectively followed-up for 1 year. The association between changes in FABP4 levels and changes in MS and its components was evaluated. Changes in other biochemical parameters, anthropometric markers and vascular data were also investigated.

Results

We observed an increase in FABP4 levels associated with MS progression and a reduction in FABP4 levels associated with MS regression. The increase in FABP4 levels was associated with the development of both triglyceridemia and low levels of high-density lipoprotein (HDL)-cholesterol, while FABP4 reductions were associated with regression of abdominal obesity, low HDL-cholesterol and the basal glycemia criteria of MS. The predictors of MS progression were positive changes in insulin and waist circumference. The only independent predictor of MS regression was reduction in FABP4.

Conclusions

Variations in circulating FABP4 levels are associated with MS progression and regression. Given the impact of FABP4 on several MS components, a causal relationship between FABP4 reduction and MS regression cannot be excluded.